doi:10.1016/j.medj.2024.10.020engPazo-Cid, RobertoGomila Pons, PaulaIntegrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?ART-2025-143491The treatment of locally advanced gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma remains a significant challenge despite advances in chemotherapy (ChT) and surgical techniques. The integration of immune checkpoint inhibitors (ICIs) into the neoadjuvant (NAT) and perioperative treatment regimens is a promising step toward improving outcomes for this patient population. The phase 2 study reported by Long et al.1 explores the combination of the novel bispecific anti-PD-1/CTLA-4 antibody2025http://zaguan.unizar.es/record/15369910.1016/j.medj.2024.10.020http://zaguan.unizar.es/record/153699oai:zaguan.unizar.es:153699Med 6, 3 (2025), 100543 [5 p.]All rights reservedhttp://www.europeana.eu/rights/rr-f/info:eu-repo/semantics/openAccess